
The Cleveland Clinic team's real-world findings presented at ESC 2026 are hypothesis-generating and need prospective confirmation but point to a low threshold for OSA screening.

Milind Desai, MD, MBA, FACC, FAHA, FESC, is Vice Chair of the Heart Vascular Thoracic Institute and Director of the Hypertrophic Cardiomyopathy Center at the Cleveland Clinic.

The Cleveland Clinic team's real-world findings presented at ESC 2026 are hypothesis-generating and need prospective confirmation but point to a low threshold for OSA screening.

Milind Desai, MD, MBA, explains the domino effect linking obesity, obstructive sleep apnea, and hypertrophic cardiomyopathy—and why treating obesity may break the chain.

September 4th 2026

September 8th 2026